VolitionRX Limited (NYSEAMERICAN:VNRX – Free Report) – Stock analysts at Zacks Research lifted their Q3 2026 earnings estimates for VolitionRX in a note issued to investors on Monday, September 14th. Zacks Research analyst S. Ralston now expects that the medical research company will post earnings of ($0.42) per share for the quarter, up from their prior forecast of ($0.78). The consensus estimate for VolitionRX’s current full-year earnings is ($2.36) per share. Zacks Research also issued estimates for VolitionRX’s Q4 2026 earnings at ($0.28) EPS and FY2026 earnings at ($1.95) EPS.
A number of other research analysts have also recently commented on the company. Benchmark reaffirmed a “hold” rating on shares of VolitionRX in a research report on Monday, August 17th. Maxim Group reiterated a “buy” rating and set a $4.00 target price on shares of VolitionRX in a research report on Thursday, June 18th. Two research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, VolitionRX presently has an average rating of “Hold” and an average price target of $28.00.
VolitionRX Trading Down 5.0%
VolitionRX stock opened at $0.27 on Thursday. The business’s 50 day simple moving average is $0.68 and its 200 day simple moving average is $2.01. VolitionRX has a 12 month low of $0.27 and a 12 month high of $14.80. The company has a market cap of $3.75 million, a price-to-earnings ratio of -0.07 and a beta of 1.10.
VolitionRX (NYSEAMERICAN:VNRX – Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The medical research company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.28). The firm had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.41 million.
VolitionRX Company Profile
VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.
The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.
Further Reading
- Five stocks we like better than VolitionRX
- 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
- Jackson’s Record Quarter Powers the Bull Case
- Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big
- AI Panic Hit Tech Stocks—But NVIDIA’s Growth Engine Is Intact
Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.
